Rodeo Therapeutics is developing small-molecule therapies designed to promote regeneration and repair of multiple tissue types by increasing tissue levels of prostaglandin PGE2. Its scientific approach targets inhibition of the prostaglandin‑degrading enzyme 15‑PGDH; preclinical studies published in Science showed that increasing PGE2 accelerates hematopoietic stem cell reconstitution after bone marrow transplant, protects against colitis, and promotes liver regeneration in animal models. The company will initially focus on developing 15‑PGDH inhibitors for inflammatory bowel disease and to promote blood cell reconstitution following bone marrow transplant. Founding scientists and advisors include Sanford Markowitz, Stanton Gerson, and Joseph Ready, based on research from Case Western Reserve University and UT Southwestern. Rodeo announced a $5.9 million Series A financing intended to provide resources to advance the development program toward human trials. No operating revenue or user metrics were disclosed in the article.

Total raised

$6M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2017